Efficacy and safety of TACE combined with MWA followed by immune checkpoint inhibitors and anti-VEGF/tyrosine kinase inhibitors in hepatocellular carcinoma beyond the up-to-7
BackgroundPrevious studies have shown that locoregional therapy combined with systemic treatment provides survival benefits with manageable safety in patients with intermediate-to-advanced large hepatocellular carcinoma (HCC). However, the optimal trea…